Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 4/2019

06.11.2018 | Original Research

Radio-pathological Correlation of 18F-FDG PET in Characterizing Gallbladder Wall Thickening

verfasst von: Vikas Gupta, K. S. Vishnu, Thakur D. Yadav, Yashwant R. Sakaray, Santosh Irrinki, B. R. Mittal, N. Kalra, K. Vaiphei

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Aim

Thick-walled gallbladder is difficult to characterize on conventional imaging. 18F-FDG PET was used to differentiate benign and malignant wall thickness and compared with histopathology.

Methods

Thirty patients with gallbladder (GB) wall thickening (focal > 4 mm and diffuse > 7 mm), underwents uspected on  ultrasound, or CT scan, and underwent 18F-FDG PET. Histopathology of the specimen was compared with imaging findings.

Results

The mean age was 48.22 ± 31.33 years with a M:F 1:4 ratio. Twenty patients had diffuse and 10 had focal thickening. On 18F-FDG PET, lesion was benign in 12, malignant in 13, and indeterminate in 5. Histopathology was malignancy in 12; benign in 18-chronic cholecystitis in 11, xanthogranulomatous in 4, IgG4 related in 2, and polyp in 1. The mean GB wall thickness was 7.79 ± 3.59 mm (10.34 malignant and 6.10 in benign, p = 0.001). At a cutoff of 8.5 mm, the sensitivity and specificity of detecting malignancy was 94% and 67%. The mean SUV uptake was 7.46 (benign 4.51, malignant 14.26, p = 0.0102). At a cutoff of 5.95, the sensitivity and specificity of detecting malignancy was 92% and 79%. For 18F-FDG PET, overall sensitivity was 91%, specificity 79%, PPV 77%, NPV 92%, and diagnostic accuracy was 84%.

Conclusion

18F-FDG PET is a reliable method of differentiation between benign and malignant thickening of the gallbladder particularly when wall thickness and SUV value is taken into account.
Literatur
1.
Zurück zum Zitat Malhotra RK, Manoharan N, Shukla NK, Rath GK. Gallbladder cancer incidence in Delhi urban: a 25-year trend analysis. Ind J Cancer. 2017;54:673–7.CrossRef Malhotra RK, Manoharan N, Shukla NK, Rath GK. Gallbladder cancer incidence in Delhi urban: a 25-year trend analysis. Ind J Cancer. 2017;54:673–7.CrossRef
2.
Zurück zum Zitat Köhn N, Maubach J, Warschkow R, Tsai C, Nussbaum DP, Candinas D, et al. High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. HPB (Oxford). 2018 Jun 8 S1365-182X(18)30819-0. https://doi.org/10.1016/j.hpb.2018.05.007. Köhn N, Maubach J, Warschkow R, Tsai C, Nussbaum DP, Candinas D, et al. High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. HPB (Oxford). 2018 Jun 8 S1365-182X(18)30819-0. https://​doi.​org/​10.​1016/​j.​hpb.​2018.​05.​007.
3.
Zurück zum Zitat Goussous N, Maqsood H, Patel K, Ferdosi H, Muhammad N, Sill AM, et al. Clues to predict incidental gallbladder cancer. Hepatobiliary Pancreat Dis Int. 2018;17:149–57.CrossRef Goussous N, Maqsood H, Patel K, Ferdosi H, Muhammad N, Sill AM, et al. Clues to predict incidental gallbladder cancer. Hepatobiliary Pancreat Dis Int. 2018;17:149–57.CrossRef
4.
Zurück zum Zitat Mitchell CH, Johnson PT, Fishman EK, Hruban RH, Raman SP. Features suggestive of gallbladder malignancy: analysis of T1, T2, and T3 tumors on cross-sectional imaging. J Comput Assist Tomogr. 2014;38:235–41.CrossRef Mitchell CH, Johnson PT, Fishman EK, Hruban RH, Raman SP. Features suggestive of gallbladder malignancy: analysis of T1, T2, and T3 tumors on cross-sectional imaging. J Comput Assist Tomogr. 2014;38:235–41.CrossRef
5.
Zurück zum Zitat Wasnik AP, Davenport MS, Kaza RK, Weadock WJ, Udager A, Keshavarzi N, et al. Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. Clin Imag. 2018;50:223–8.CrossRef Wasnik AP, Davenport MS, Kaza RK, Weadock WJ, Udager A, Keshavarzi N, et al. Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. Clin Imag. 2018;50:223–8.CrossRef
7.
Zurück zum Zitat Kishore R, Nundy S, Mehrotra S, Mehta N, Mangla V, Lalwani S. Strategies for differentiating gallbladder carcinoma from xanthogranuomatous cholecystitis – a tertiary care centre experience. Ind J Surg Oncol. 2017;8:554–9.CrossRef Kishore R, Nundy S, Mehrotra S, Mehta N, Mangla V, Lalwani S. Strategies for differentiating gallbladder carcinoma from xanthogranuomatous cholecystitis – a tertiary care centre experience. Ind J Surg Oncol. 2017;8:554–9.CrossRef
8.
Zurück zum Zitat Rao RV, Kumar A, Sikora SS, Saxena R, Kapoor VK. Xanthogranulomatous cholecystitis: differentiation from associated gall bladder carcinoma. Trop Gastroenterol. 2005;26:31–3.PubMed Rao RV, Kumar A, Sikora SS, Saxena R, Kapoor VK. Xanthogranulomatous cholecystitis: differentiation from associated gall bladder carcinoma. Trop Gastroenterol. 2005;26:31–3.PubMed
9.
Zurück zum Zitat Kim SJ, Lee JM, Lee JY, Kim SH, Han JK, Choi BI, et al. Analysis of enhancement pattern of flat gallbladder wall thickening on MDCT to differentiate gallbladder cancer from cholecystitis. Am J Roentgenol. 2008;191:765–71.CrossRef Kim SJ, Lee JM, Lee JY, Kim SH, Han JK, Choi BI, et al. Analysis of enhancement pattern of flat gallbladder wall thickening on MDCT to differentiate gallbladder cancer from cholecystitis. Am J Roentgenol. 2008;191:765–71.CrossRef
10.
Zurück zum Zitat Sureka B, Singh VP, Rajesh SR, Laroia S, Bansa K, Rastogi A, et al. Computed tomography (CT) and magnetic resonance (MR) findings in xanthogranulomatous cholecystitis: retrospective analysis of pathologically proven 30 cases – tertiary care experience. Pol J Radiol. 2017;82:327–32.CrossRef Sureka B, Singh VP, Rajesh SR, Laroia S, Bansa K, Rastogi A, et al. Computed tomography (CT) and magnetic resonance (MR) findings in xanthogranulomatous cholecystitis: retrospective analysis of pathologically proven 30 cases – tertiary care experience. Pol J Radiol. 2017;82:327–32.CrossRef
11.
Zurück zum Zitat Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197:260–5.CrossRef Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR Am J Roentgenol. 2011;197:260–5.CrossRef
12.
Zurück zum Zitat Covera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18 F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2007;206:57–65.CrossRef Covera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18 F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg. 2007;206:57–65.CrossRef
13.
Zurück zum Zitat Annunziata S, Pizzuto AP, Caldarella C, Galiandro F, sadeghi R, Treglia G. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: a meta-analysis. World J Gastroenterol. 2015;21:11481–8.CrossRef Annunziata S, Pizzuto AP, Caldarella C, Galiandro F, sadeghi R, Treglia G. Diagnostic accuracy of fluorine-18-fluorodeoxyglucose positron emission tomography in gallbladder cancer: a meta-analysis. World J Gastroenterol. 2015;21:11481–8.CrossRef
14.
Zurück zum Zitat Oe A, Kawabe J, Toril K, Higashiyama S, Kotani J, Hayashi T, et al. Distinguishing between benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med. 2006;20:699–703.CrossRef Oe A, Kawabe J, Toril K, Higashiyama S, Kotani J, Hayashi T, et al. Distinguishing between benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med. 2006;20:699–703.CrossRef
15.
Zurück zum Zitat Roms-Font C, Gomez-Rio M, Rodriguez-Fernandez A, Jimenez-Haffernan A, Sanchez RS, Llamas-Elvira JM. Ability of FDG-PET/CT in the detection of gallbladder cancer. J Surg Oncol. 2014;109:218–24.CrossRef Roms-Font C, Gomez-Rio M, Rodriguez-Fernandez A, Jimenez-Haffernan A, Sanchez RS, Llamas-Elvira JM. Ability of FDG-PET/CT in the detection of gallbladder cancer. J Surg Oncol. 2014;109:218–24.CrossRef
16.
Zurück zum Zitat Anderson CD, Rice MH, Pinson W, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose pet imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90–7.CrossRef Anderson CD, Rice MH, Pinson W, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose pet imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8:90–7.CrossRef
17.
Zurück zum Zitat Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time –point 18F-FDG PET for evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633–8.PubMed Nishiyama Y, Yamamoto Y, Fukunaga K, Kimura N, Miki A, Sasakawa Y, et al. Dual-time –point 18F-FDG PET for evaluation of gallbladder carcinoma. J Nucl Med. 2006;47:633–8.PubMed
18.
Zurück zum Zitat Jindal G, Singal S, Nagi B, Mittal A, Mittal S, Singal R. Role of multidetector computed tomography (MDCT) in evaluation of gallbladder malignancy and its pathological correlation in an indian rural center. Maedica – J Clin Med. 2018;13:55–60.CrossRef Jindal G, Singal S, Nagi B, Mittal A, Mittal S, Singal R. Role of multidetector computed tomography (MDCT) in evaluation of gallbladder malignancy and its pathological correlation in an indian rural center. Maedica – J Clin Med. 2018;13:55–60.CrossRef
19.
Zurück zum Zitat Hwang JP, Lim I, Cho EH, Kim BI, Choi CW, Lim SM. Prognostic value of SUV max measured by Fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with gallbladder cancer. Nucl Med Mol Imag. 2014;48:114–20.CrossRef Hwang JP, Lim I, Cho EH, Kim BI, Choi CW, Lim SM. Prognostic value of SUV max measured by Fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography in patients with gallbladder cancer. Nucl Med Mol Imag. 2014;48:114–20.CrossRef
20.
Zurück zum Zitat Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol. 2003;84:74–81.CrossRef Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol. 2003;84:74–81.CrossRef
21.
Zurück zum Zitat Furukawa H, Ikuma H, Assakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100:494–9.CrossRef Furukawa H, Ikuma H, Assakura K, Uesaka K. Prognostic importance of standardized uptake value on F-18 fluorodeoxyglucose-positron emission tomography in biliary tract carcinoma. J Surg Oncol. 2009;100:494–9.CrossRef
22.
Zurück zum Zitat Rodriguez-Fernandez A, Gomez-Rio M, Llamas-Elvira JM, Ortega-Lozano S, Ferron-Orihuela JA, Ramia-Angel JM, et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-Dglucose for gallbladder cancer diagnosis. Am J Surg. 2004;188:171–5.CrossRef Rodriguez-Fernandez A, Gomez-Rio M, Llamas-Elvira JM, Ortega-Lozano S, Ferron-Orihuela JA, Ramia-Angel JM, et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy-Dglucose for gallbladder cancer diagnosis. Am J Surg. 2004;188:171–5.CrossRef
Metadaten
Titel
Radio-pathological Correlation of 18F-FDG PET in Characterizing Gallbladder Wall Thickening
verfasst von
Vikas Gupta
K. S. Vishnu
Thakur D. Yadav
Yashwant R. Sakaray
Santosh Irrinki
B. R. Mittal
N. Kalra
K. Vaiphei
Publikationsdatum
06.11.2018
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 4/2019
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-018-0176-2

Weitere Artikel der Ausgabe 4/2019

Journal of Gastrointestinal Cancer 4/2019 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.